E10.90 E66.99 E11.90 E13.90 E78.9 I10.90 I10.90 N18.9 Q96.9 Q87.1 P05.9 E23.0 E71.1
Conditions
Interventions
Group 1: Testing of patients with abovementioned diseases for early atherosclerotic changes
Measurement of functional Intima-Media-thickness of the carotid artery,
Photography of the retinal fundus (
Sponsors
Pädiatrische Endokrinologie und DiabetologieKlinik für Allgemeine PädiatrieZentrum für Kinder- und Jugendmedizin
Eligibility
Sex/Gender
All
Age
4 Years to 18 Years
Inclusion criteria
Inclusion criteria: Einschlusskriterien 1. General: a. Signed informed consent b. Age = 7 - 97. age appropriate percentile (Deutsche synthetische Normkurve, patients of different ethnicity respective percentiles). 6. Healthy controls a. Absence of diseases with influence on atherosclerosis risk. 7. Hypercholesterolemia a. total cholesterol > 250 mg/dl or LDL cholesterol >160 mg/dl or LDL/HDL ratiot >3 b. Treatment with medication against hypercholesterolemia and cholesterol levels that don't fit 7a. 8. Arterial Hypertension a. Arterial Hypertension according to the guidelines of Deutsche Gesellschaft für pädiatrische Kardiologie 9. Renal insufficiency a. Chronic renal insufficiency, at least grade III (Crea Clearance <60ml/min, calculated by new Schwartz-formula; 0,413 x lenght in cm / blood creatinine in mg/dl 10. Ullrich-Turner syndrome a. Diagnosis of Ullrich-Turner-syndrome or Ullrich-Turner syndrome mosaic by chromosomal analysis 11. Methylmalonaziduria und Propionaziduria or other metabolic diseases a. Patients with methylmalonaziduria or propionaziduria or other metabolic diseases diagnosed by generally accepted criteria (metabolic laboratory tests, genetics) b. Therapy with carnitine 12. Prader Willi syndrome a. Prader Willi syndrome (genetically diagnosed) 13. Growth hormone deficiency a. Growth hormone deficiency (diagnosed with two pathologic stimulation tests) b. therapy with recombinant Growth hormone or completed therapy with recombinant Growth hormone 14. Birth small for gestational age a. Length and/or weight SDS < -2 at birth b. therapy with recombinant growth hormone or c. length SDS < -2,5 und growth velocity SDS < 0 and difference of at least one SDS to genetic target length at beginning of growth hormone replacement For another arm of the study, following inclusion criteria are applied: Inclusion criteria: a. Prepubertal patients aged 4-10 years b. Presence of Growth hormone deficiency, Small for gestational age birth with indication for growth hormone treatment, Ullrich Turner Syndrome, Prader Willi Syndrome OR absence of atherosclerosis risk modifying diseases c. Before start of growth hormone therapy OR after at least 1 year of growth hormone therapy d. Signed informed consent
Exclusion criteria
Exclusion criteria: Ausschlusskriterien 1. General: a. Acute inflammatory or infectious disease at the time of examination/venous puncture b. Temperaturer >38,5°C at the time of examination/venous puncture c. Diseases with vascular malformation d. Thrombophilia 2. Diabetes mellitus type 1 a. other forms of diabetes mellitus (e.g. Cystic fibrosis related Diabetes, monogenic forms of diabetes). 3. Diabetes mellitus type 2 none 4. Cystic fibrosis related Diabetes mellitus a. Acute pulmonary exacerbation with fever and/or intravenous antibiotic therapy b. pulmonary transplantation c. Listed for pulmonary transplantation 5. Obesity a. Syndromic forms of obesity (e.g. Prader Willi syndrome), Cushings syndrome, hypothyreoidism without therapy b. Pathologic oral glucose tolerance test (in this case inclusion in group 3). 6. Healthy controls a. preterm birth 38,5°C) d. Vascular malformation or diseases, that usually comprise vascular malformation e. Thrombophilia f. Preterm birth before gestational age of 35 + 0 weeks
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Evaluation of diagnostic techniques for early diagnosis of atherosclerotic changes in childhood and compilation of normative values for healthy children. | — |
Secondary
| Measure | Time frame |
|---|---|
| *Comparison of different diagnostic techniques and correlation of results on the early diagnosis of atherosclerotic changes. *Analysis of differences in early atherosclerotic changes in patient groups compared to control group. *Correlation of results to clnical characteristics like disease duration, quality of therapy (e.g. HbA1c), duration of therapy etc. *Correlation of results to known risk factors for atherosclerosis like smoking, weight, blood pressure, sedentary lifestyle etc. *Compilation of risk profiles / mutual risk constellations with latent class models. | — |
Countries
Germany
Contacts
Public ContactMichael Wurm
Pädiatrische Endokrinologie und DiabetologieKlinik für Allgemeine PädiatrieZentrum für Kinder- und Jugendmedizin
Outcome results
None listed